News

TherapeuticsMD, Inc. (NASDAQ: TXMD), an innovative, leading women’s healthcare Company, today reported financial results for the first quarter ended March 31, 2021.

“I am pleased with our ongoing

Clovis Oncology, Inc. (NASDAQ:CLVS) reported financial results for the quarter ended March 31, 2021, and provided an update on the Company’s clinical development programs and regulatory and

Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that on May 3, 2021 the Compensation Committee of Puma’s Board of Directors approved the grant of inducement

Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) today announced financial results for the first quarter ended March 31, 2021, and provided a corporate update.

“We are excited by the continuing

Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today reported recent business highlights and first quarter 2021 financial results.

“This quarter, we have continued our

Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that management will be participating in fireside chats at the following investor conferences:

• 
  BofA
  

Regulatory News:

NANOBIOTIX (Paris:NANO) (NASDAQ:NBTX) (Euronext : NANO – NASDAQ: NBTX – the ‘‘Company’’), a late-stage clinical biotechnology company pioneering physics-based approaches to

Clovis Oncology, Inc. (Nasdaq: CLVS) today announced that its President and Chief Executive Officer, Patrick J. Mahaffy, will present at the Bank of America 2021 Health Care Conference on Tuesday

Regulatory News:

NANOBIOTIX (Euronext: NANO – NASDAQ: NBTX – the ‘‘Company’’), a late-stage clinical biotechnology company pioneering physics-based approaches to expand treatment possibilities

Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX: AUP) (the “Company”) today announced that it will release its first quarter 2021 financial results on Thursday, May 6, 2021, after the markets

Sangamo Therapeutics, Inc. (NASDAQ: SGMO), a genomic medicine company, today announced upcoming data presentations at the 24^th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT)

Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that the Company has scheduled the release of its first quarter 2021 financial results after the market closes

Regulatory News:

Transgene (Paris:TNG) (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, today announces its business

Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH) today announced that it will report its first quarter 2021 financial results on Tuesday, May 4, 2021.

In connection with the earnings release

Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, will host a conference call at 1:30 p.m. PDT/4:30 p.m. EDT on Thursday, May 6, 2021, following the release of its first quarter

(Unaudited data)

Clovis Oncology, Inc. (NASDAQ: CLVS) will announce its first quarter 2021 financial results on Wednesday, May 5, 2021, before the open of the US financial markets. Clovis’ senior management will

Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX: AUP) (the “Company”) today announced that members of the executive management team will participate in a fireside chat during the 2021 Bloom Burton

Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that on April 12, 2021 the Compensation Committee of Puma’s Board of Directors approved the grant of inducement

Regulatory News:

NANOBIOTIX (Euronext: NANO – NASDAQ: NBTX – the ‘‘Company’’) (Paris:NANO) (NASDAQ:NBTX), a late-stage clinical biotechnology company pioneering physics-based approaches to expand

Regulatory News:

Strasbourg, France, April 12, 2021, 05:45 pm CET – Transgene (Paris:TNG), a biotech company that designs and develops virus-based immunotherapeutics against cancer, today

Clovis Oncology, Inc. (NASDAQ: CLVS) announced that Phase 1 clinical data from studies exploring Rubraca in combination with Xtandi for the treatment of advanced prostate cancer (RAMP) and Rubraca

Regulatory News:

Transgene (Paris:TNG) (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapeutics against cancer, today announces initial promising results

Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX: AUP) (Aurinia or the Company) today presented additional efficacy data from the AURA-LV and AURORA 1 pivotal trials of LUPKYNIS™ (voclosporin) in

Regulatory News:

NANOBIOTIX (Euronext: NANO – NASDAQ: NBTX – the ‘‘Company’’), a late-stage clinical biotechnology company pioneering physics-based approaches to expand treatment possibilities